The Discounted Cash Flow (DCF) valuation of BridgeBio Pharma Inc (BBIO) is (36.59) USD. With the latest stock price at 42.83 USD, the upside of BridgeBio Pharma Inc based on DCF is -185.4%.
Based on the latest price of 42.83 USD and our DCF valuation, BridgeBio Pharma Inc (BBIO) is a sell. selling BridgeBio stocks now will result in a potential gain of 185.4%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.9% - 9.5% | 7.7% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (120.75) - (25.45) | (36.59) |
| Upside | -381.9% - -159.4% | -185.4% |